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Abstract
Background: Bisphosphonate Osteonecrosis of the Jaw (BRONJ) 
is a newly recognized condition reported in patients treated with 
aminobisphosphonates (BF). BRONJ is defined as the presence of 
exposed necrotic alveolar bone that does not resolve over a period 
of 8 weeks in a patient taking bisphosphonates who has not had 
radiotherapy to the jaw. Treatment protocols have been outlined, 
but trials and outcomes of treatment and long-term follow-up data 
are not yet available. In 2004 an expert panel outlined recommen-
dations for the management of bisphosphonate-associated osteone-
crosis of the jaws. Through the histological study of the oral mu-
cosa over the bone necrosis and around the osteonecrosis area in 8 
patients affected by BRONJ at III stage, the authors highlight the 
inappropriateness of the local mucosal flaps to cover the losses of 
substance of the jaw, BF-related.
Methods: Mucosa tissue was taken from 8 patients, affected by 
BRONJ, III stage. The samples taken from the mucosa around and 
over the osteonecrosis area were fixed with formalin and an ematos-
silina-eosin dichromatic coloring was carried out.
Results: The samples of mucosa showed pathognomonic signs of 
cell suffering that prove that in these patients using local mucosa 
flaps is inappropriate.
Conclusions: The authors suggest that only a well vascularized flap 
as free flap must be used to cover the osteonecrosis area in patients 
with BRONJ stage III. Because of the structural instability of the 
mucosa in patients suffering of osteonecrosis Bf related the local 
flaps are prone to ulceration and to relapse.
Keywords: Osteonecrosis of the jaw; Bisphosphonates; Amino-
bisphosphonates
Introduction
Bisphosphonates (BP) are a widely used class of drugs with 
known efficacy in the prevention and treatment of osteopo-
rosis, Paget’s disease of bone, hypercalcemia of malignancy, 
osteolytic lesions of multiple myeloma and metastatic osteo-
lytic lesion from breast, lung and other soft tissue tumours 
[1].
The development of BRONJ lesions appears to be as-
sociated with previous dental traumatic injury, like tooth ex-
traction [2, 3], in the majority of cases. Spontaneous cases 
occur in less than 30% of patients especially localized in ar-
eas with very thin overlying mucosa [4]. BRONJ typically 
occurs in patients who are receiving intravenous BP treat-
ment. However, an increasing frequency of osteonecrosis of 
the jaw has been reported recently in people who receive oral 
BPs.
Although numerous studies strongly suggest an associa-
tion between BP and BRONJ, the true incidence, etiology, 
pathogenesis, and natural history of this condition have yet 
to be elucidated.
There are several pathogenic hypothesis about the mech-
anisms that cause the BRONJ [5]. BPs are thought to func-
tion by inhibiting at least one enzyme of the intracellular 
mevalonate pathway in osteoclasts [5, 6]. Inhibition of this 
pathway prevents the modification of important signaling 
proteins, which disrupts osteoclast function and leads to in-
direct apoptotic cell death. Antiangiogenic and antineoplas-
tic properties have been attributed to BPs.
Most authors emphasize the role of BP in the inhibi-
tion of the osteoclastic activity as the drugs that lead to the 
beginning of osteonecrosis [7]. Bisphosphonate mediated 
inhibition of osteoclastic function leads to decreased bone 
resorption and inhibits normal bone turnover. Once incorpo-
rated into mineralized bone, BPs, stay in the bone for a long 
time and have a terminal half-life of many years. As a result, 
patients who discontinue BP therapy still may be at risk of 
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developing BRONJ several years after they stop taking the 
drug.
However, this theory of the osteoclast inhibition does 
not explain the elective localization of the disease in max-
illofacial area, supporting instead the hypothesis that other 
mechanisms determine the BRONJ. In reference to what was 
stated in literature about oesophageal mucosal and gastric 
lesions in patients treated with oral BP, some authors under-
lined that the BP given i.v. have a direct cytotoxic effect on 
oral mucosal keratinocytes because of a leakage of the drug 
on the overlying mucosa caused by the dental extractions or 
by some micro-traumatisms [8]. There is clear documenta-
tion of BP toxicity to gastrointestinal epithelia. For example, 
alendronate and risedronate inhibit cell proliferation in vitro 
by means of inhibition of farnesil-disphosphonate synthase, 
the same enzyme which is the target of BP in osteoclasts [8, 
9]. The clinical effects of this phenomenon are well recog-
nized in the form of upper gastrointestinal side effects from 
BP use, and also as ulceration occurring in patients who suck 
BP tablets [10]. Tooth extraction or other dental trauma re-
sult in local release of BP. If the local concentration of drugs 
is high enough, it inhibits proliferation of adjacent epithelial 
cells [11] and slows healing of the physical breach in the 
mucosa, BP uptake into bone is in direct proportion to the 
local rate of bone turnover and the alveolar ridges have high 
turnover [12]. This evidence could explain the elective lo-
calization in maxilla-facial region. In this anatomic area the 
alveolar ligament, the periosteum, the gingival mucosa and 
the dental neck are connected together: this peculiar struc-
ture may cause, also without any traumatic events, a contact 
between BP and the soft tissue [13, 14]. A direct cytotoxic ef-
fect on the mucosa epithelia cells could explain the necrosis 
of the flaps of the oral mucosa harvested to cover the bones 
in BRONJ stage II and III.
In some reports minimal surgical procedures such as 
sequestrectomy and coverage of the exposed bone with lo-
cal mucosal flaps are preferred. The authors agree with the 
above-mentioned non-invasive procedure of demolition, but 
not with the use of the local mucosa flaps. In their experience 
the oral mucosa appears instable, prone to diastase and ulcer-
ation. Indeed, this type of reconstruction causes a high inci-
dence of infections and relapses characterized by the bone 
exposure and let them prefer some other different treatments.
The Authors suggest: sequestrectomy and minimal inva-
sive debridement of the necrotic bone and then reconstruc-
tion with microsurgical flaps.
Any procedures must be completed with 0.2% chlorhex-
idine mouthwash and antibiotic therapy.
Thanks to the histological analysis of the mucosa sam-
ples taken 2 cm around the osteonecrosis area and the muco-
sa over and close to the osteonecrosis, in 8 patients affected 
by BRONJ stage III, the authors highlighted the histopatho-
logical changes that underline the unsuitability of the mu-
cosa flaps to fill in the losses of substance.
Materials and Methods
Mucosa tissue was taken from 8 patients, affected by 
BRONJ, III stage, which have been under treatment with BP 
i.v. (zolendronate) for at least 2 years. They either suffered 
from bone metastases caused by breast cancer and prostate 
cancer or from osteolytic lesions as a consequence of Mul-
tiple Mieloma.
Histological sampling was made at supralesion and per-
ilesional seat (distance from the necrotic bone 2 cm max). 
The samples were fixed with formalin and an ematossilina-
eosin dichromatic coloring was carried out.
Each preparation was subjected to morphological evalu-
ation by optical microscopy. The taken parameters were: ac-
Figure 1. An inflammation of the mucosa with massive presence of plasma cells and granulocytes in the connective 
tissue was found in the samples taken from above the necrotic bone (A). (B) A conservation of the connective tissue 
isto-architecture and of deeper epithelial layers was found on the samples of the mucosa surrounding the osteonecro-
sis. The inflammatory infiltrate is poorly represented and small areas of cellular plasma densification are rarely notice-
able. Despite the mucosa deep layers keep their original architecture, the superficial ones are characterized by the 
presence of swollen and hypereosinophilic cells with a picnotic nucleus, which represents the signs of pathognomonic 
cell suffering.
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anthosis, papillomatosis, histological architecture.
 
Results
An inflammation of the mucosa with massive presence of 
plasma cells and granulocytes in the connective tissue was 
found in the samples taken from above the necrotic bone. The 
histo-architecture of the connective tissue and of the mucosa 
appears modified: stratification is visible only in some areas 
and the papillomatosis is clearly noticeable on the slide. The 
most superficial layers are made up of few mature cells and 
are characterized by phenomena of ulceration and fray. Also, 
a phenomenon of interstitial edema is evident. (Fig. 1A).
On the contrary, a conservation of the connective tissue 
isto-architecture and of deeper epithelial layers was found 
on the samples of the mucosa surrounding the osteonecro-
sis. Buds are well defined and regular-shaped. The inflam-
matory infiltrate is poorly represented and small areas of 
cellular plasma densification are rarely noticeable. Despite 
the mucosa deep layers keep their original architecture, the 
superficial ones are characterized by the presence of swollen 
and hypereosinophilic cells with a picnotic nucleus, which 
represents the signs of pathognomonic cell suffering. (Fig. 
1B) Thickness has also significantly increased: indeed the 
granular layer is made up of 16 to 20 orders of cells (usually 
2 - 6).
Discussion
  
The results of the histopathological examination of the ar-
eas affected by BRONJ have shown a reactivity of the tis-
sue to the bone necrosis, and especially a serious damage 
on the epithelial cells. The clear existence of alterations of 
the perilesion mucosa (swollen cells, hiperesinophilia, pyk-
nosis) without the typical connective tissue inflammatory 
infiltration of supra-lesional mucosa, is the evidence that 
BP cause cellular suffering of the keratinocytes of the oral 
mucosa. The leakage of BP from the jaw bone, as a conse-
quence of the dental trauma, causes a cell suffering of the 
surrounding oral mucosa, similar to the pathologies of sto-
matitis [14], gastritis and esophagitis [15] occurred while 
administrating BP × os. The process appears to be the same: 
inhibition of the farnesyl disphosphnate synthase enzyme of 
the keratinocytes and reduction of the levels of VEGF (vas-
cular endothelium growth factor) due to the action of BP on 
endothelial cells [5]. As mentioned above, a leak of the drug 
at soft tissues level adherent to the periosteum, is likely to 
happen as a result of dental trauma. This event produces a 
histo-architectural deterioration of the mucosa caused by the 
contact between BP and basal layers of the same mucosa. 
Furthermore, due to the features of the parodontal anatomy, 
the contact between BP and the soft tissues is likely to occur 
also in the absence of traumatic events, thus justifying the 
onset of BRONJ even without any dental extraction.
Based on these results, the mucosa surrounding the os-
teonecrosis area is inert, unstable and prone to ulcerations 
and infections. Therefore, the coverage of bone substance 
loss by local mucosa flaps in BRONJ stage III is not rec-
ommended, because the arise of diastases of the sutures and 
septic phenomena are the results of the structural instability 
and alteration of the mucosal keratinocytes.
Similarly, it is not recommended to use mucosal flaps 
taken from distant anatomical sites, far from the exposure 
bone (ex cheek mucosa). Indeed, once the mucosa is trans-
posed on the necrotic bone, as far as it appears healthy and 
eutrophic, and coming into contact with BP accumulated in 
the osteonecrosis area, it undergoes the local toxic effect of 
BP incurring the isto-architectural changes, previously de-
scribed for the perilesional mucosa.
The authors suggest the use of microsurgical flap, as a 
chimeric flaps alt-vastus lateralis muscle (Fig. 2) to cover 
the osteonecrosis area of the jaw after a minimal invasive 
sequestrectomy of the affected bone.
Source of Support
Nil.
Figure 2. Tha authors suggest the use of microsurgical flap, as a chimeric flaps alt-vastus lateralis muscle to cover the 
osteonecrosis area of the jaw after a minimal invasive sequestrectomy of the affected bone.
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